Interestingly, this study also identified TIM-1 as a B-cell-specific checkpoint molecule, suggesting that TIM-1 expression on B cells may serve as a potential therapeutic target for tumor immunotherapy (33). The gene discussed is HAVCR1; the disease is neoplasm.